Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?

In the last decades significant progress has been achieved in the biological understanding of non-small-cell lung cancer (NSCLC) and its tumor heterogeneity has become more evident. The identification of novel tumor targets with different pathways has stimulated the search for anti-tumor agents with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transl Lung Cancer Res
Hauptverfasser: Pilz, Lothar R, Manegold, Christian, Schmid-Bindert, Gerald
Format: Artigo
Sprache:Inglês
Veröffentlicht: Pioneer Bioscience Publishing Company 2012
Schlagworte:
Review Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4367593/
https://ncbi.nlm.nih.gov/pubmed/25806152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2011.12.08
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge